Theravance Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M |
| Selling, general & administrative | $73.7M | $69.2M | $70.1M | $67.1M | $99.3M |
| Research and development | $37.4M | $37.6M | $40.6M | $63.4M | $193.7M |
| Operating expenses | $111.1M | $111.3M | $113.5M | $143.3M | $313.1M |
| Operating income | -$3.6M | -$46.9M | -$56.0M | -$92.0M | -$257.8M |
| Interest expense | $2.5M | $2.5M | $2.4M | $6.4M | $8.5M |
| Pretax income | $129.2M | -$44.6M | -$49.3M | -$92.8M | -$265.2M |
| Income tax expense | $23.4M | $11.8M | $5.9M | $9,000 | -$151,000 |
| Net income | $105.9M | -$56.4M | -$55.2M | $872.1M | -$199.4M |
| Balance Sheet | |||||
| Cash and equivalents | $167.8M | $37.8M | $39.5M | $298.2M | $90.0M |
| Current assets | $418.5M | $161.1M | $133.5M | $353.5M | $249.9M |
| Total assets | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M |
| Current liabilities | $38.3M | $32.1M | $24.8M | $28.7M | $58.6M |
| Stockholders' equity | $296.7M | $175.5M | $213.0M | $441.8M | -$338.6M |
| Cash Flow Statement | |||||
| Cash from operations | $238.5M | -$11.5M | -$27.0M | -$187.0M | -$207.9M |
| Depreciation and amortization | $1.5M | $1.6M | $1.9M | $2.6M | $3.5M |
| Stock-based compensation | $18.5M | $21.4M | $25.4M | $39.7M | $62.1M |
| Capital expenditure | $42,000 | $332,000 | $2.5M | $572,000 | $3.4M |
| Free cash flow | $238.5M | -$11.9M | -$29.5M | -$187.6M | -$211.3M |
| Share repurchases | — | $445,000 | $197.1M | $128.8M | — |
| Impairments | $0 | $4.5M | $0 | — | — |
Shares outstanding 51.6M · Free float 38.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.